SCHEMBL6315883

SCHEMBL6315883

NC(=O)c1c(-c2cccnc2)noc1NC(=O)c1ccccc1F

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.52
NPC1 O15118 4/20 0.52
RAB9A P51151 4/20 0.52
MAPT P10636 3/20 0.48
DYRK1A Q13627 1/20 0.47
GAA P10253 4/20 0.46
HPGD P15428 1/20 0.46
ALDH1A1 P00352 7/20 0.45
KDM4E B2RXH2 3/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
HTT P42858 1/20 0.44
TDP1 Q9NUW8 2/20 0.43
GLA P06280 2/20 0.42
TP53 P04637 2/20 0.41
THRB P10828 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
ATR Q13535 1/20 0.41
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6318137 0.89 DYRK1A (0.50) SMN1; SMN2NPC1RAB9AMAPTDYRK1A
SCHEMBL6317088 0.88 HTT (0.53) SMN1; SMN2NPC1RAB9AMAPTGAA
SCHEMBL6318780 0.87 SMN1; SMN2 (0.54) SMN1; SMN2NPC1RAB9AMAPTDYRK1A
SCHEMBL6316610 0.87 HTT (0.54) SMN1; SMN2NPC1RAB9AMAPTGAA
SCHEMBL27610012 0.87 NPC1 (0.48) SMN1; SMN2NPC1RAB9AMAPTDYRK1A
SCHEMBL6314663 0.85 CYP2C9 (0.46) SMN1; SMN2NPC1RAB9AMAPTHPGD
SCHEMBL6315761 0.83 CYP11B1 (0.52) SMN1; SMN2RAB9AMAPTDYRK1AGAA
SCHEMBL27591643 0.81 NPC1 (0.48) SMN1; SMN2NPC1RAB9AMAPTDYRK1A
SCHEMBL6316620 0.80 SMN1; SMN2 (0.44) SMN1; SMN2NPC1RAB9AMAPTGAA
SCHEMBL6318236 0.80 NTRK1 (0.53) SMN1; SMN2NPC1RAB9AMAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 SMN1; SMN2 2766/4885NPC1 3741/4885RAB9A 1754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.